Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib

被引:1
作者
Masanori Ochi [1 ]
Toshiro Kamoshida [1 ]
Atsushi Ohkawara [1 ]
Haruka Ohkawara [1 ]
Nobushige Kakinoki [1 ]
Shinji Hirai [1 ]
Akinori Yanaka [2 ]
机构
[1] Department of Gastroenterology, Hitachi General Hospital
[2] Hitachi Medical Education and Research Center, University of Tsukuba
关键词
Hepatocellular carcinoma; Surrogate marker; Multikinase inhibitor-associated hand-foot skin reaction; Sorafenib; Intervention by pharmacists;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
AIM To investigate the relationship between the onsets of multikinase inhibitor(MKI)-associated hand-foot skin reaction(HFSR) and prognosis under intervention by pharmacists after the introduction of sorafenib.METHODS We conducted a retrospective study involving 40 patients treated with sorafenib. Intervention by pharmacists began at the time of treatment introduction and continued until the appearance of symptomatic exacerbation or non-permissible adverse reactions. We examined the relationship between MKI-associated HFSR and overall survival(OS) after the initiation of treatment.RESULTS The median OS was 10.9 mo in the MKI-associated HFSR group and 3.4 mo in the no HFSR group, showing a significant difference in multivariate analysis. A multivariate analysis of the time to treatment failure indicated that the intervention by pharmacists and MKI-associated HFSR were significant factors. The median cumulative dose and the mean medication possession ratio were significantly higher in the intervention group than in the non-intervention group. A borderline significant difference was observed in terms of OS in this group.CONCLUSION Intervention by pharmacists increased drug adherence. Under increased adherence, MKI-associated HFSR was an advantageous surrogate marker. Intervention by healthcare providers needs to be performed for adequate sorafenib treatment.
引用
收藏
页码:3155 / 3162
页数:8
相关论文
共 50 条
  • [41] Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Pomej, Katharina
    Balcar, Lorenz
    Scheiner, Bernhard
    Semmler, Georg
    Meischl, Tobias
    Mandorfer, Mattias
    Reiberger, Thomas
    Mueller, Christian
    Trauner, Michael
    Pinter, Matthias
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1485 - 1493
  • [42] A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction
    Yeh, Chun-Nan
    Huang, Wen-Kuan
    Lu, Chun-Wei
    Chen, Chiao-Ping
    Lin, Sheng-Hsuan
    Pan, Yi-Ru
    Wu, Chiao-En
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2023, 201 (12) : 5540 - 5545
  • [43] Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
    Di Costanzo, Giovan Giuseppe
    de Stefano, Giorgio
    Tortora, Raffaella
    Farella, Nunzia
    Addario, Luigi
    Lampasi, Filippo
    Lanza, Alfonso Galeota
    Cordone, Gabriella
    Imparato, Michele
    Caporaso, Nicola
    FUTURE ONCOLOGY, 2015, 11 (06) : 943 - 951
  • [44] Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
    Cho, Ju-Yeon
    Paik, Yong-Han
    Lim, Ho Yeong
    Kim, Young Gon
    Lim, Hyo Keun
    Min, Yang Won
    Gwak, Geum-Youn
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    Yoo, Byung Chul
    LIVER INTERNATIONAL, 2013, 33 (06) : 950 - 957
  • [45] Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib
    Spira, Daniel
    Fenchel, Michael
    Lauer, Ulrich M.
    Claussen, Claus D.
    Gregor, Michael
    Bitzer, Michael
    Horger, Marius
    ACADEMIC RADIOLOGY, 2011, 18 (01) : 89 - 96
  • [46] Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
    Chu, David
    Lacouture, Mario E.
    Weiner, Elizabeth
    Wu, Shenhong
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 11 - 19
  • [47] Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
    Vincenzi, Bruno
    Santini, Daniele
    Russo, Antonio
    Addeo, Raffaele
    Giuliani, Francesco
    Montella, Liliana
    Rizzo, Sergio
    Venditti, Olga
    Frezza, Anna Maria
    Caraglia, Michele
    Colucci, Giuseppe
    Del Prete, Salvatore
    Tonini, Giuseppe
    ONCOLOGIST, 2010, 15 (01) : 85 - 92
  • [48] The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
    Balagula, Yevgeniy
    Wu, Shenhong
    Su, Xiao
    Feldman, Darren R.
    Lacouture, Mario E.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1773 - 1781
  • [49] Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials
    Cabibbo, Giuseppe
    Cucchetti, Alessandro
    Camma, Calogero
    Casadei-Gardini, Andrea
    Celsa, Ciro
    Rizzo, Giacomo Emanuele Maria
    Johnson, Philip
    Ercolani, Giorgio
    FUTURE ONCOLOGY, 2019, 15 (29) : 3411 - 3422
  • [50] HandFoot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
    Nakano, Kazuhiko
    Komatsu, Kenji
    Kubo, Taro
    Natsui, Shinsuke
    Nukui, Akinori
    Kurokawa, Shinsuke
    Kobayashi, Minoru
    Morita, Tatsuo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (10) : 1023 - 1029